Piper Sandler Forecasts Strong Price Appreciation for Inspire Medical Systems (NYSE:INSP) Stock

Inspire Medical Systems (NYSE:INSP) had its price target raised by Piper Sandler from $60.00 to $70.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler‘s target price would indicate a potential upside of 3.67% from the company’s current price.

INSP has been the subject of a number of other reports. UBS Group initiated coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 target price for the company. Robert W. Baird increased their target price on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Mizuho set a $75.00 price target on Inspire Medical Systems in a research report on Tuesday, October 13th. Stifel Nicolaus lifted their target price on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Finally, Evercore set a $54.00 target price on Inspire Medical Systems in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Inspire Medical Systems has an average rating of “Hold” and an average price target of $71.24.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $67.52 on Tuesday. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The company has a 50 day moving average price of $68.69 and a 200 day moving average price of $58.82. The stock has a market capitalization of $1.95 billion, a P/E ratio of 14.61, a price-to-earnings-growth ratio of 5.37 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company had revenue of $206.69 million during the quarter, compared to analysts’ expectations of $204.31 million. During the same quarter last year, the company posted $0.38 EPS. The firm’s revenue was down 7.9% compared to the same quarter last year. On average, research analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Several institutional investors and hedge funds have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund grew its position in shares of Inspire Medical Systems by 8.4% during the third quarter. Oregon Public Employees Retirement Fund now owns 6,462 shares of the company’s stock worth $448,000 after buying an additional 500 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Inspire Medical Systems in the third quarter valued at $276,000. Vise Technologies Inc. acquired a new stake in Inspire Medical Systems in the third quarter valued at $252,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Inspire Medical Systems during the 3rd quarter valued at $312,000. Finally, Pinnacle Wealth Planning Services Inc. boosted its stake in Inspire Medical Systems by 19.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock valued at $81,000 after acquiring an additional 194 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter revenue of approximately $206.7 million, exceeding the $204.3 million consensus estimate. Adjusted earnings of $0.14 per share also topped published estimates of roughly $0.09–$0.10. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Management’s commentary pointed toward a potential recovery in the company’s reimbursement environment, which could support procedure volumes and growth if payer-related pressures ease. Inspire Medical Tops Consensus But Misses the Whisper
• Neutral Sentiment: The earnings call was closely watched by analysts for updates on reimbursement, demand and the company’s path back to sustained growth following recent operating challenges. Inspire Medical Systems Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined 7.9% from the year-ago quarter, while earnings fell to $0.14 per share from $0.38. The results indicate that reimbursement and utilization headwinds remain material despite the quarterly beat. Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Although INSP exceeded official consensus forecasts, reports indicate it missed higher “whisper” expectations, limiting the positive impact of the headline earnings beat and contributing to the weaker share-price reaction. Inspire Medical Tops Consensus But Misses the Whisper

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.